Medtronic PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Medtronic plc reported robust financial results for fiscal year 2026, driven by significant growth across its key business segments.
NYSE
Medtronic plc reported a 4% increase in net sales and a significant rise in GAAP net income for fiscal year 2025, fueled by strong performance in its Cardiovascular, Neuroscience, and Diabetes segments, while also announcing plans to separate its Diabetes business.
NYSE
10-K: Medtronic's Annual Report Reveals Financials, Strategic Focus, and Risk Factors for Fiscal Year 2024
Medtronic's 2024 annual report details its financial performance, strategic initiatives, and various risk factors impacting its global operations.